title: Considerations When Evaluating Cost-Effectiveness Analyses of Novel Stroke Prevention Therapies.
authors.forename: Sheldon M
authors.initials: SM
authors.lastname: Singh
authors.forename: Harindra C
authors.initials: HC
authors.lastname: Wijeysundera
mesh_terms: D000925:Anticoagulants; D001281:Atrial Fibrillation; D003362:Cost-Benefit Analysis; D006801:Humans; D019057:Quality-Adjusted Life Years; D020521:Stroke; D014859:Warfarin
chemical_list: D000925:Anticoagulants; D014859:Warfarin